Pablo Gajate

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

Dean F. Bajorin, J. Alfred Witjes, Jürgen E. Gschwend et al. · New England Journal of Medicine · 2021 · 1K citations · Full text

Medicine, Oncology, Surgery +17

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study

Martin Schüler, Byoung Chul Cho, Cyrus Sayehli et al. · The Lancet Oncology · 2019 · 174 citations

Medicine, Oncology, Pharmacology +11

Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

Jaume Capdevila, Nicola Fazio, Carlos López et al. · Journal of Clinical Oncology · 2021 · 113 citations · Full text

Medicine, Oncology, Pharmacology +16

Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms

James C. Yao, Jonathan Strosberg, Nicola Fazio et al. · Endocrine Related Cancer · 2021 · 106 citations

Medicine, Oncology, Pharmacology +17

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors

Iván Márquez‐Rodas, Federico Longo, María E. Rodríguez-Ruiz et al. · Science Translational Medicine · 2020 · 84 citations

Life Sciences, Immunology, Oncology +16